bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Authors: Wang Ruizhong , Bhat-Nakshatri Poornima , Padua Maria B. , Prasad Mayuri S , Anjanappa Manjushree , Jacobson Max , Finnearty Courtney , Sefcsik Victoria , McElyea Kyle , Redmond Rachael , Sandusky George , Penthala Narsimha , Crooks Peter A , Liu Jianguo , Zimmers Teresa , Nakshatri Harikrishna
Published: April 2023

The effect of mammary tumor growth in PyMT+ mice on cardiac parameters
Figure S3 from Mutual Influence of ROS, pH, and CLIC1 Membrane Protein in the Regulation of G1–S Phase Progression in Human Glioblastoma Stem Cells
Authors: Peretti Marta , Raciti Federica Maddalena , Carlini Valentina , Verduci Ivan , Sertic Sarah , Barozzi Sara , Garré Massimiliano , Pattarozzi Alessandra , Daga Antonio , Barbieri Federica , Costa Alex , Florio Tullio , Mazzanti Michele
Published: April 2023

Quantitative real-time PCR for CLIC5 protein.
Figure S7 from IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma
Authors: Long Kristen B. , Tooker Graham , Tooker Evan , Luque Santiago Lombo , Lee Jae W. , Pan Xiaoqing , Beatty Gregory L.
Published: April 2023

IL-6Ralpha expression in murine PDAC tumors
Figure S5 from IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma
Authors: Long Kristen B. , Tooker Graham , Tooker Evan , Luque Santiago Lombo , Lee Jae W. , Pan Xiaoqing , Beatty Gregory L.
Published: April 2023

Anti-IL-6Ralpha antibodies can be detected in stromal tissue surrounding malignant PDAC cells
Figure S1 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
Authors: Marzi Laetitia , Agama Keli , Murai Junko , Difilippantonio Simone , James Amy , Peer Cody J. , Figg William D. , Beck Daniel , Elsayed Mohamed S.A. , Cushman Mark , Pommier Yves
Published: April 2023

LMP135 induces marginal body weight loss in mice
Table S4 from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Authors: Machida Yukino , Nakagawa Makoto , Matsunaga Hironori , Yamaguchi Masayuki , Ogawara Yoko , Shima Yutaka , Yamagata Kazutsune , Katsumoto Takuo , Hattori Ayuna , Itoh Masato , Seki Takahiko , Nishiya Yumi , Nakamura Koichi , Suzuki Kanae , Imaoka Tomoki , Baba Daichi , Suzuki Makoto , Sampetrean Oltea , Saya Hideyuki , Ichimura Koichi , Kitabayashi Issay
Published: April 2023

Table S4 shows mean Kp, brain and Kp, cerebrum values of DS-1001a in mice.
Table S1 from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Authors: Machida Yukino , Nakagawa Makoto , Matsunaga Hironori , Yamaguchi Masayuki , Ogawara Yoko , Shima Yutaka , Yamagata Kazutsune , Katsumoto Takuo , Hattori Ayuna , Itoh Masato , Seki Takahiko , Nishiya Yumi , Nakamura Koichi , Suzuki Kanae , Imaoka Tomoki , Baba Daichi , Suzuki Makoto , Sampetrean Oltea , Saya Hideyuki , Ichimura Koichi , Kitabayashi Issay
Published: April 2023

Table S1 shows data collection and refinement statistics for analysis of IDH1(R132C)/NADPH/compound A co-crystal.
Figure S4 from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Authors: Machida Yukino , Nakagawa Makoto , Matsunaga Hironori , Yamaguchi Masayuki , Ogawara Yoko , Shima Yutaka , Yamagata Kazutsune , Katsumoto Takuo , Hattori Ayuna , Itoh Masato , Seki Takahiko , Nishiya Yumi , Nakamura Koichi , Suzuki Kanae , Imaoka Tomoki , Baba Daichi , Suzuki Makoto , Sampetrean Oltea , Saya Hideyuki , Ichimura Koichi , Kitabayashi Issay
Published: April 2023

DS-1001b permeates the blood-brain barrier and inhibits tumor growth in an orthotopic PDX model.
Figure S7 from Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer
Authors: Hao Na , Shen Wenzhi , Du Renle , Jiang Shan , Zhu Junyong , Chen Yanan , Huang Chongbiao , Shi Yi , Xiang Rong , Luo Yunping
Published: April 2023

Figure S7 shows that the summary of PDE3A.
Figure S1 from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Authors: Machida Yukino , Nakagawa Makoto , Matsunaga Hironori , Yamaguchi Masayuki , Ogawara Yoko , Shima Yutaka , Yamagata Kazutsune , Katsumoto Takuo , Hattori Ayuna , Itoh Masato , Seki Takahiko , Nishiya Yumi , Nakamura Koichi , Suzuki Kanae , Imaoka Tomoki , Baba Daichi , Suzuki Makoto , Sampetrean Oltea , Saya Hideyuki , Ichimura Koichi , Kitabayashi Issay
Published: April 2023

Pyrograms for glioblastoma cells.
Supplementary Figure 5 from Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
Authors: Nagel Remco , Avelar Ana Teresa , Aben Nanne , Proost Natalie , van de Ven Marieke , van der Vliet Jan , Cozijnsen Miranda , de Vries Hilda , Wessels Lodewyk F. A. , Berns Anton
Published: April 2023

Supplementary figure 5A. Graphs showing the synergy scores of the combination matrix of cisplatin and the ATR inhibitor VE-822 tested in a panel of 6 human SCLC cell lines. B. Western blot showing pCHK1 levels after treatment with 2 Î¼M VE-822 for 4 hours.
Figure S2 from Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer
Authors: Hao Na , Shen Wenzhi , Du Renle , Jiang Shan , Zhu Junyong , Chen Yanan , Huang Chongbiao , Shi Yi , Xiang Rong , Luo Yunping
Published: April 2023

Figure S2 shows that PDE3A was highly expressed in patients with metastatic breast cancer.
Figure S1 from Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer
Authors: Hao Na , Shen Wenzhi , Du Renle , Jiang Shan , Zhu Junyong , Chen Yanan , Huang Chongbiao , Shi Yi , Xiang Rong , Luo Yunping
Published: April 2023

Figure S1 shows the expression and location of PDE3A.
Supplementary Figure 1C + D from Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
Authors: Nagel Remco , Avelar Ana Teresa , Aben Nanne , Proost Natalie , van de Ven Marieke , van der Vliet Jan , Cozijnsen Miranda , de Vries Hilda , Wessels Lodewyk F. A. , Berns Anton
Published: April 2023

Supplementary figure 1C. Sequencing tracks of a part of the Zwilch gene targered by a second unique sgRNA, with the wildtype sequence (top) and sgRNA treated sequence (bottom) shown. D. Tide analysis showing editing efficiency of the second Zwilch targeting sgRNA
Supplementary Table S2 from Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Authors: Pishas Kathleen I. , Drenberg Christina D. , Taslim Cenny , Theisen Emily R. , Johnson Kirsten M. , Saund Ranajeet S. , Pop Ioana L. , Crompton Brian D. , Lawlor Elizabeth R. , Tirode Franck , Mora Jaume , Delattre Olivier , Beckerle Mary C. , Callen David F. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Summary of Ewing sarcoma KDM1A expression studies and genes consistently induced/repressed following SP-2509 treatment
Supplemental Video 1. Intravital imaging of iRGD TPNs in a xenograft model of pancreatic cancer from iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer
Authors: Lo Justin H. , Hao Liangliang , Muzumdar Mandar D. , Raghavan Srivatsan , Kwon Ester J. , Pulver Emilia M. , Hsu Felicia , Aguirre Andrew J. , Wolpin Brian M. , Fuchs Charles S. , Hahn William C. , Jacks Tyler , Bhatia Sangeeta N.
Published: April 2023

Intravital imaging of a subcutaneous pancreatic cancer xenograft (MIA PaCa-2) showing distribution of PEGylated iRGD TPNs (green) in tumor cell compartments surrounding abnormal tumor blood vessels. Collagen visualized through second-harmonic generation is displayed in magenta. Images in this video were captured at a depth of 60 μm from the edge of the exposed tumor. Each frame of 0.25 sec represents 5 min of elapsed time, starting 3 minutes after injection of the particles. Please refer to Figure S5 for reference scale bar.
Supplemental Information and Figures S1-S7 from iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer
Authors: Lo Justin H. , Hao Liangliang , Muzumdar Mandar D. , Raghavan Srivatsan , Kwon Ester J. , Pulver Emilia M. , Hsu Felicia , Aguirre Andrew J. , Wolpin Brian M. , Fuchs Charles S. , Hahn William C. , Jacks Tyler , Bhatia Sangeeta N.
Published: April 2023

Figure S1. In vitro optimization of iRGD TPNs in PDAC cell lines; Figure S2. Dual knockdown using TPNs; Figure S3. In vitro and in vivo properties and function of PEGylated iRGD TPNs; Figure S4. Overview of organoid image analysis; Figure S5. iRGD TPN-mediated delivery of siRNA in models of pancreatic cancer; Figure S6. iRGD-mediated TPN uptake and NRP-1 expression in the tumor vasculature; Figure S7. Stromal elements in a KPC-derived orthotopic tumor section following iRGD TPN administration.
Supplementary Figure 3 from Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Authors: Pishas Kathleen I. , Drenberg Christina D. , Taslim Cenny , Theisen Emily R. , Johnson Kirsten M. , Saund Ranajeet S. , Pop Ioana L. , Crompton Brian D. , Lawlor Elizabeth R. , Tirode Franck , Mora Jaume , Delattre Olivier , Beckerle Mary C. , Callen David F. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Cytotoxic effects of the irreversible KDM1A inhibitors GSK-LSD1 and Tranylcypromine
Supplementary Table S4 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects
Authors: Huaqi Yin , Caipeng Qin , Qiang Wang , Yiqing Du , Xiang Dai , Xu Tang , Xiaowei Zhang , Qing Li , Shijun Liu , Tao Xu
Published: April 2023

Univariable and multivariable analysis for ccRCC patients' overall survival using Cox's proportional hazards model
Supplementary Table S3 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects
Authors: Huaqi Yin , Caipeng Qin , Qiang Wang , Yiqing Du , Xiang Dai , Xu Tang , Xiaowei Zhang , Qing Li , Shijun Liu , Tao Xu
Published: April 2023

The sequence of gene primer and small interfering RNAs
Supplementary Table S1 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects
Authors: Huaqi Yin , Caipeng Qin , Qiang Wang , Yiqing Du , Xiang Dai , Xu Tang , Xiaowei Zhang , Qing Li , Shijun Liu , Tao Xu
Published: April 2023

Clinicopathological characteristics of patients with ccRCC
Figures s1, s2, s3 and s4 from Hyaluronic Acid Binding to TLR4 Promotes Proliferation and Blocks Apoptosis in Colon Cancer
Authors: Makkar Sarbjeet , Riehl Terrence E. , Chen Baosheng , Yan Yan , Alvarado David M. , Ciorba Matthew A. , Stenson William F.
Published: April 2023

supplementary figures
Supplementary Figure 2 from Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy
Authors: Creevey Laura , Bleach Rachel , Madden Stephen F. , Toomey Sinead , Bane Fiona T. , Varešlija Damir , Hill Arnold D. , Young Leonie S. , McIlroy Marie
Published: April 2023

Characterisation of ZR75aro-LetR. Validation of ER AR siRNA
Supplemental data from Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice
Authors: Gu Lubing , Zhang Hailong , Liu Tao , Draganov Alexander , Yi Sha , Wang Binghe , Zhou Muxiang
Published: April 2023

Supplemental data
Supplemental Figure 6 from Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy
Authors: Creevey Laura , Bleach Rachel , Madden Stephen F. , Toomey Sinead , Bane Fiona T. , Varešlija Damir , Hill Arnold D. , Young Leonie S. , McIlroy Marie
Published: April 2023

Correlation between CYP19 amplification and SGK3 expression.
Supplementary Table S1 from The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics
Authors: Martens-de Kemp Sanne R. , Brink Arjen , van der Meulen Ida H. , de Menezes Renée X. , te Beest Dennis E. , Leemans C. René , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table S1. Primer sequences for quantitative real-time PCR.
Supplementary Table S5 from In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
Authors: Anisuzzaman Abu Syed Md , Haque Abedul , Wang Dongsheng , Rahman Mohammad Aminur , Zhang Chao , Chen Zhengjia , Chen Zhuo Georgia , Shin Dong M. , Amin A.R.M. Ruhul
Published: April 2023

Supp lementary Table S5: Dose reduction indices for erlotinib
Supplementary Table S4 from In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
Authors: Anisuzzaman Abu Syed Md , Haque Abedul , Wang Dongsheng , Rahman Mohammad Aminur , Zhang Chao , Chen Zhengjia , Chen Zhuo Georgia , Shin Dong M. , Amin A.R.M. Ruhul
Published: April 2023

Supplementary Table S4: Dose reduction indices for BKM120
Supplementary Figures S1-S10 from In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
Authors: Anisuzzaman Abu Syed Md , Haque Abedul , Wang Dongsheng , Rahman Mohammad Aminur , Zhang Chao , Chen Zhengjia , Chen Zhuo Georgia , Shin Dong M. , Amin A.R.M. Ruhul
Published: April 2023

This file contains supplementary information for publication
Supplementary Methods from Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein–Mediated Resistance to Temozolomide in Glioblastoma
Authors: Salaroglio Iris C. , Mujumdar Prashant , Annovazzi Laura , Kopecka Joanna , Mellai Marta , Schiffer Davide , Poulsen Sally-Ann , Riganti Chiara
Published: April 2023

The file contains supporting methods (chemical synthesis, cell phenotyping).
Figure S1 from Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells
Authors: Wang Rui , Li Ying , Gong Ping , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

The effect of FLT3-ligand on GSH levels and ATO-induced apoptosis.
Supplementary Figure S6 from Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation
Authors: Stefan Nikolas , Gébleux Rémy , Waldmeier Lorenz , Hell Tamara , Escher Marie , Wolter Fabian I. , Grawunder Ulf , Beerli Roger R.
Published: April 2023

In vivo evaluation of CD30-specific ADCs in mouse xenograft model.
Supplementary Figure S5 from Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation
Authors: Stefan Nikolas , Gébleux Rémy , Waldmeier Lorenz , Hell Tamara , Escher Marie , Wolter Fabian I. , Grawunder Ulf , Beerli Roger R.
Published: April 2023

In vivo evaluation of HER2- and CD30-specific ADCs in mouse xenograft models.
Supplementary Figure S2 from Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation
Authors: Stefan Nikolas , Gébleux Rémy , Waldmeier Lorenz , Hell Tamara , Escher Marie , Wolter Fabian I. , Grawunder Ulf , Beerli Roger R.
Published: April 2023

In vitro cytotoxicity assays with HER2-positive and -negative cell lines using sortase A-conjugated, anthracycline-based anti-HER2 ADCs.
Supplementary Movie S4 from Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells
Authors: Koo Chuay-Yeng , Giacomini Caterina , Reyes-Corral Marta , Olmos Yolanda , Tavares Ignatius A. , Marson Charles M. , Linardopoulos Spiros , Tutt Andrew N. , Morris Jonathan D.H.
Published: April 2023

Live images showing compound 43 delays mitosis and induces mitotic catastrophe in CA SKBR3 cells. Representative time-lapse video images showing GFP-α-tubulin expressing SKBR3 cells incubated in growth medium containing compound 43 (5 µM) for 48 hours.
Supporting Video 12 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Molecular dynamics simulations of the Eg5(D130A)-ispinesib complex.
Supporting Video 10 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Molecular dynamics simulations of the Eg5(L214A)-ispinesib complex.
Supplementary Table 1 from Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation
Authors: Simmons John K. , Michalowski Aleksandra M. , Gamache Benjamin J. , DuBois Wendy , Patel Jyoti , Zhang Ke , Gary Joy , Zhang Shuling , Gaikwad Snehal , Connors Daniel , Watson Nicholas , Leon Elena , Chen Jin-Qiu , Kuehl W. Michael , Lee Maxwell P. , Zingone Adriana , Landgren Ola , Ordentlich Peter , Huang Jing , Mock Beverly A.
Published: April 2023

Statistical Data and SNPS
Supporting Video 06 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Time lapse imaging of U2OS-Eg5(L214A) expressing cells exposed to 10 nM ispinesib and followed for 16h. Cells are arrested in mitosis.
Supporting Video 02 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Time lapse imaging of U2OS cells exposed to 10 nM Arry-520 and followed for 16h. Cells are arrested in mitosis.
Supplementary Figure 1 from Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer
Authors: Li Jie , Wang Ruixin , Kong Yifan , Broman Meaghan M. , Carlock Colin , Chen Long , Li Zhiguo , Farah Elia , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

some data which support the conclusion in Figure 1, which further demonstrate the synergistic effect between two drugs.
Supplemental Table 1 from Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma
Authors: Lacey Alexandra , Hedrick Erik , Cheng Yating , Mohankumar Kumaravel , Warren Melanie , Safe Stephen
Published: April 2023

Antibodies, oligonucleotides and primers
Supplement 4. Next generation sequencing results for second round screen. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Authors: Shi Chang-Xin , Kortüm K. Martin , Zhu Yuan Xiao , Bruins Laura A. , Jedlowski Patrick , Votruba Patrick G. , Luo Moulun , Stewart Robert A. , Ahmann Jonathan , Braggio Esteban , Stewart A. Keith
Published: April 2023

We performed secondary screening in quadruplicate and next generation sequencing was again performed in the resistant cells. Sequencing results were listed.
Supplementary Tables S1-S4 and Supplementary Figures S1-S6 from Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance
Authors: Bagchi Atrish , Haidar Jaafar N. , Eastman Scott W. , Vieth Michal , Topper Michael , Iacolina Michelle D. , Walker Jason M. , Forest Amelie , Shen Yang , Novosiadly Ruslan D. , Ferguson Kathryn M.
Published: April 2023

Supplementary Table S1 - Therapeutic antibody induced EGFR ECR mutations; Supplementary Table S2 - Mean SPR KD values for binding of wild type (WT) and cetuximab resistance variants of sEGFR to immobilized Fab fragments from cetuximab (FabC225) and necitumumab (Fab11F8) and to EGF; Supplementary Table S3 - Crystallographic data collection and refinement statistics; Supplementary Table S4 - Changes in experimental binding and DSC4.1 computed energy terms for interaction of cetuximab (C225) and necitumumab (11F8) with wild type and epitope mutated EGFR variants; Supplementary Figure S1 - Binding of necitumumab and cetuximab to LK2 and HELA cells; Supplementary Figure S2 - Electron density near R468 in sEGFRd3-S468R/Fab11F8 structure; Supplementary Figure S3 - Comparison of the paratopes of necitumumab and panitumumab; Supplementary Figure S4 - Necitumumab exhibits structural plasticity in binding to sEGFRd3-S468R; Supplementary Figure S5 - Location of the epitope substitutions in the experimental test set and evaluation of the side chain conformations modeled with DSC4.1; Supplementary Figure S6 - CDR dynamics for necitumumab and cetuximab when bound to three cetuximab resistance variants, evaluated by MD simulations
Figure S5 from Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers
Authors: Maust Joel D. , Frankowski-McGregor Christy L. , Bankhead Armand , Simeone Diane M. , Sebolt-Leopold Judith S.
Published: April 2023

Effects of trametinib and palbociclib alone and in combination on growth and expression of various signaling proteins
Figure S3 from Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers
Authors: Maust Joel D. , Frankowski-McGregor Christy L. , Bankhead Armand , Simeone Diane M. , Sebolt-Leopold Judith S.
Published: April 2023

Evaluation of in vivo efficacy to the combination of trametinib and palbociclib in L3.6pl tumor-bearing animals
Supplementary table S2 from Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Authors: Fujita Motomichi , Yamamoto Tetsuya , Iyoda Takuya , Fujisawa Tatsuya , Sasada Manabu , Nagai Reo , Kudo Chikako , Otsuka Kazuki , Kamiya Sadahiro , Kodama Hiroaki , Fukai Fumio
Published: April 2023

Primer information
Supplementary Movie S1 from Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Authors: Fujita Motomichi , Yamamoto Tetsuya , Iyoda Takuya , Fujisawa Tatsuya , Sasada Manabu , Nagai Reo , Kudo Chikako , Otsuka Kazuki , Kamiya Sadahiro , Kodama Hiroaki , Fukai Fumio
Published: April 2023

Time lapse evaluation of cell scattering (control)
Supplementary Figure and Figure legend from Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Authors: Fujita Motomichi , Yamamoto Tetsuya , Iyoda Takuya , Fujisawa Tatsuya , Sasada Manabu , Nagai Reo , Kudo Chikako , Otsuka Kazuki , Kamiya Sadahiro , Kodama Hiroaki , Fukai Fumio
Published: April 2023

This file shows the supplementary figures (S1-S8) and their legends.
Supplementary Figure 1 from A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors
Authors: Chamberlain Chester E. , German Michael S. , Yang Katherine , Wang Jason , VanBrocklin Henry , Regan Melanie , Shokat Kevan M. , Ducker Gregory S. , Kim Grace E. , Hann Byron , Donner David B. , Warren Robert S. , Venook Alan P. , Bergsland Emily K. , Lee Danny , Wang Yucheng , Nakakura Eric K.
Published: April 2023

Pharmacodynamic studies of everolimus and sapanisertib treated PDX-PNETs using Western blot analysis of mTOR pathway targets.
Supplementary Table S1 from Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling
Authors: Nakai Sho , Tamiya Hironari , Imura Yoshinori , Nakai Takaaki , Yasuda Naohiro , Wakamatsu Toru , Tanaka Takaaki , Outani Hidetatsu , Takenaka Satoshi , Hamada Kenichiro , Myoui Akira , Araki Nobuhito , Ueda Takafumi , Yoshikawa Hideki , Naka Norifumi
Published: April 2023

Supplementary Table S1 shows information of antibodies used in this study.
Supplementary Figure 3 from Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications
Authors: Saidu Nathaniel Edward Bennett , Noé Gaëlle , Cerles Olivier , Cabel Luc , Kavian-Tessler Niloufar , Chouzenoux Sandrine , Bahuaud Mathilde , Chéreau Christiane , Nicco Carole , Leroy Karen , Borghese Bruno , Goldwasser François , Batteux Frédéric , Alexandre Jérôme
Published: April 2023

Concentration-dependant cellular effects of DMF in OVCAR3 cells.
Supplementary Figure 2 from Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications
Authors: Saidu Nathaniel Edward Bennett , Noé Gaëlle , Cerles Olivier , Cabel Luc , Kavian-Tessler Niloufar , Chouzenoux Sandrine , Bahuaud Mathilde , Chéreau Christiane , Nicco Carole , Leroy Karen , Borghese Bruno , Goldwasser François , Batteux Frédéric , Alexandre Jérôme
Published: April 2023

High concentrations of DMF causes caspase 3 and PARP cleavages in several cancer cell lines.
Supplementary Figure S1 from Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling
Authors: Nakai Sho , Tamiya Hironari , Imura Yoshinori , Nakai Takaaki , Yasuda Naohiro , Wakamatsu Toru , Tanaka Takaaki , Outani Hidetatsu , Takenaka Satoshi , Hamada Kenichiro , Myoui Akira , Araki Nobuhito , Ueda Takafumi , Yoshikawa Hideki , Naka Norifumi
Published: April 2023

Supplementary Figure S1 shows tumor weights at the end point, body weights during treatment, HE staining and immunohistochemical staining in Hewga-CCS and MP-CCS-SY xenograft tumors of all three treatment groups.
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6 from Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance
Authors: Lifshitz Veronica , Priceman Saul J. , Li Wenzhao , Cherryholmes Gregory , Lee Heehyoung , Makovski-Silverstein Adar , Borriello Lucia , DeClerck Yves A. , Yu Hua
Published: April 2023

Supplemental Figure 1. Bone marrow stromal cells enhance NB resistance to etoposide; Supplemental Figure 2. Overexpression of S1PR1 in CHLA-171 cells activates STAT3 and renders cells resistant to etoposide via JAK2/STAT3 signaling; Supplemental Figure 3. Elevated S1PR1 expression and STAT3 activation in etoposide-resistant CHLA-171 NB cells; Supplemental Figure 4. Taxol and JAK inhibitor effects on NB drug resistance; Supplemental Figure 5. Stattic and W146 inhibit STAT3 phosphorylation in NB drug resistant cells; Supplemental Figure 6. Crosstalk between NB cells and BM-MSC cells upregulates Sphk1.
Supplementary Table S1 from Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
Authors: Duplaquet Leslie , Figeac Martin , Leprêtre Frédéric , Frandemiche Charline , Villenet Céline , Sebda Shéhérazade , Sarafan-Vasseur Nasrin , Bénozène Mélanie , Vinchent Audrey , Goormachtigh Gautier , Wicquart Laurence , Rousseau Nathalie , Beaussire Ludivine , Truant Stéphanie , Michel Pierre , Sabourin Jean-Christophe , Galateau-Sallé Françoise , Copin Marie-Christine , Zalcman Gérard , De Launoit Yvan , Fafeur Véronique , Tulasne David
Published: April 2023

Supplementary Table S1: Detailed annotation of the somatic mutations in the 58 RTKs, KRAS, PI3KCA, and TP53
Supplementary Figures and Legends from Blockade of Glutathione Metabolism in IDH1-Mutated Glioma
Authors: Tang Xiaoying , Fu Xiao , Liu Yang , Yu Di , Cai Sabrina J. , Yang Chunzhang
Published: April 2023

Supplementary Figures 1 and 2 shows further information of RNA interference and cytotoxicity assays
Supplementary Figure S5 from Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
Authors: Duplaquet Leslie , Figeac Martin , Leprêtre Frédéric , Frandemiche Charline , Villenet Céline , Sebda Shéhérazade , Sarafan-Vasseur Nasrin , Bénozène Mélanie , Vinchent Audrey , Goormachtigh Gautier , Wicquart Laurence , Rousseau Nathalie , Beaussire Ludivine , Truant Stéphanie , Michel Pierre , Sabourin Jean-Christophe , Galateau-Sallé Françoise , Copin Marie-Christine , Zalcman Gérard , De Launoit Yvan , Fafeur Véronique , Tulasne David
Published: April 2023

Supplementary Figure S5: Effect of ligand stimulation and TKI treatment on KIT and TRKB tyrosine phosphorylation with somatic mutations
Figure S7 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Authors: Panowski Siler H. , Kuo Tracy C. , Zhang Yi , Chen Amy , Geng Tao , Aschenbrenner Laura , Kamperschroer Cris , Pascua Edward , Chen Wei , Delaria Kathy , Farias Santiago , Bateman Marjorie , Dushin Russell G. , Chin Sherman M. , Van Blarcom Thomas J. , Yeung Yik Andy , Lindquist Kevin C. , Chunyk Allison G. , Kuang Bing , Han Bora , Mirsky Michael , Pardo Ingrid , Buetow Bernard , Martin Thomas G. , Wolf Jeffrey L. , Shelton David , Rajpal Arvind , Strop Pavel , Chaparro-Riggers Javier , Sasu Barbra J.
Published: April 2023

Antibody analytics and sequences.
Figure S5 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Authors: Panowski Siler H. , Kuo Tracy C. , Zhang Yi , Chen Amy , Geng Tao , Aschenbrenner Laura , Kamperschroer Cris , Pascua Edward , Chen Wei , Delaria Kathy , Farias Santiago , Bateman Marjorie , Dushin Russell G. , Chin Sherman M. , Van Blarcom Thomas J. , Yeung Yik Andy , Lindquist Kevin C. , Chunyk Allison G. , Kuang Bing , Han Bora , Mirsky Michael , Pardo Ingrid , Buetow Bernard , Martin Thomas G. , Wolf Jeffrey L. , Shelton David , Rajpal Arvind , Strop Pavel , Chaparro-Riggers Javier , Sasu Barbra J.
Published: April 2023

Pharmacokinetics of BCMA bispecific and ADC in cynomolgus monkeys.
Supplementary Figures from Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
Authors: Li Fu , Ulrich Michelle , Jonas Mechthild , Stone Ivan J. , Linares Germein , Zhang Xinqun , Westendorf Lori , Benjamin Dennis R. , Law Che-Leung
Published: April 2023

S1. Antitumor activity and intratumoral drug release by hIgG-vcMMAE. S2: Depleting TAMs attenuate the activity of hIgG-vcMMAE. S3. Impaired FcgR binding with G1V1 variant
Supplementary Figure Legends from Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
Authors: Li Fu , Ulrich Michelle , Jonas Mechthild , Stone Ivan J. , Linares Germein , Zhang Xinqun , Westendorf Lori , Benjamin Dennis R. , Law Che-Leung
Published: April 2023

Legends of supplementary Figure S1, S2 and S3
Figure S2 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Authors: Panowski Siler H. , Kuo Tracy C. , Zhang Yi , Chen Amy , Geng Tao , Aschenbrenner Laura , Kamperschroer Cris , Pascua Edward , Chen Wei , Delaria Kathy , Farias Santiago , Bateman Marjorie , Dushin Russell G. , Chin Sherman M. , Van Blarcom Thomas J. , Yeung Yik Andy , Lindquist Kevin C. , Chunyk Allison G. , Kuang Bing , Han Bora , Mirsky Michael , Pardo Ingrid , Buetow Bernard , Martin Thomas G. , Wolf Jeffrey L. , Shelton David , Rajpal Arvind , Strop Pavel , Chaparro-Riggers Javier , Sasu Barbra J.
Published: April 2023

BCMA bispecific is activity in the presence of soluble BCMA and APRIL.
Supplementary Figure legends Tables and RSRC2 minigene sequence from TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing
Authors: Liu Tieju , Sun Huizhi , Zhu Dongwang , Dong Xueyi , Liu Fang , Liang Xiaohui , Chen Chen , Shao Bing , Wang Meili , Wang Yi , Sun Baocun
Published: April 2023

Supplementary Figure legends; Table S1, S4, S7, S8, and RSRC2 minigene sequence. Table S1: The increased splicing factors expression induced by PTX treatment in MDA-MB-231 cells; Table S4. All AS events selected for validation were confirmed by VeriQuest SYBR Green qPCR; Table S7: The relationship of TRA2A, CALUl, CALUs, RSRC2l, RSRC2s, PALMl, PALMs mRNA and TRA2A protein expression with PTXR of TNBC; Table S8: The relationship of TRA2A, CALUl, CALUs, RSRC2l, RSRC2s, PALMl and PALMs mRNA with TRA2A protein expression.
Supplementary Figure S2 from TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing
Authors: Liu Tieju , Sun Huizhi , Zhu Dongwang , Dong Xueyi , Liu Fang , Liang Xiaohui , Chen Chen , Shao Bing , Wang Meili , Wang Yi , Sun Baocun
Published: April 2023

qRT-PCR showed that MELK, CEACAM1, LMCD1 and RFWD2 AS events weren't shown during PTX treatment.
Figure S4 from A Novel Theranostic Strategy for MMP-14–Expressing Glioblastomas Impacts Survival
Authors: Mohanty Suchismita , Chen Zixin , Li Kai , Morais Goreti Ribeiro , Klockow Jessica , Yerneni Ketan , Pisani Laura , Chin Frederick T. , Mitra Siddharta , Cheshier Samuel , Chang Edwin , Gambhir Sanjiv Sam , Rao Jianghong , Loadman Paul M. , Falconer Robert A. , Daldrup-Link Heike E.
Published: April 2023

Immunofluorescent confocal images for MMP-14 expression in pcGBM39 tumors
Supplementary Video S1 from Sentinel Lymph Node–Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model
Authors: Tanaka Yuya , Araki Koji , Tanaka Shingo , Miyagawa Yoshihiro , Suzuki Hiroshi , Kamide Daisuke , Tomifuji Masayuki , Uno Kosuke , Kimura Eiko , Yamashita Taku , Ueda Yasuji , Shiotani Akihiro
Published: April 2023

Time-lapse imaging of the anti-tumor effect of BioKnife against HSC-3-M3.
Supplementary Video S1 Description and Methods from Sentinel Lymph Node–Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model
Authors: Tanaka Yuya , Araki Koji , Tanaka Shingo , Miyagawa Yoshihiro , Suzuki Hiroshi , Kamide Daisuke , Tomifuji Masayuki , Uno Kosuke , Kimura Eiko , Yamashita Taku , Ueda Yasuji , Shiotani Akihiro
Published: April 2023

Time-lapse imaging of the anti-tumor effect of BioKnife against HSC-3-M3.
Supplementary Figure S2 from Sentinel Lymph Node–Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model
Authors: Tanaka Yuya , Araki Koji , Tanaka Shingo , Miyagawa Yoshihiro , Suzuki Hiroshi , Kamide Daisuke , Tomifuji Masayuki , Uno Kosuke , Kimura Eiko , Yamashita Taku , Ueda Yasuji , Shiotani Akihiro
Published: April 2023

Preliminary experiments for lymph node metastasis (LNM) rate per animal in an orthotopic tongue squamous cell carcinoma (SCC) xenograft mouse model with LNM by using a highly metastatic human SCC cell line, HSC-3-M3.
Supplementary Figure S1 from Sentinel Lymph Node–Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model
Authors: Tanaka Yuya , Araki Koji , Tanaka Shingo , Miyagawa Yoshihiro , Suzuki Hiroshi , Kamide Daisuke , Tomifuji Masayuki , Uno Kosuke , Kimura Eiko , Yamashita Taku , Ueda Yasuji , Shiotani Akihiro
Published: April 2023

Gene maps of the wild-type Sendai virus (SeV), M gene-deleted SeV (rSeV/dM) and BioKnife.
Figure S2 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
Authors: Leconet Wilhem , Liu He , Guo Ming , Le Lamer-Déchamps Sophie , Molinier Charlotte , Kim Sae , Vrlinic Tjasa , Oster Murielle , Liu Fang , Navarro Vicente , Batra Jaspreet S. , Noriega Adolfo Lopez , Grizot Sylvestre , Bander Neil H.
Published: April 2023

PSMA and CD3 expression of targeted cells
Supplementary Tables S1-S2 and Supplementary Figures S1-S10 from A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin–Drug Conjugate (LDC)
Authors: Shimomura Osamu , Oda Tatsuya , Tateno Hiroaki , Ozawa Yusuke , Kimura Sota , Sakashita Shingo , Noguchi Masayuki , Hirabayashi Jun , Asashima Makoto , Ohkohchi Nobuhiro
Published: April 2023

Supplementary Figure S1. SDS-PAGE and HPLC of rBC2LCN-PE38 (LDC); Supplementary Figure S2. Analysis of cancer stem cell (CSC) marker expression in 6 PDAC cell lines; Supplementary Figure S3. Top 10 highlighted lectins that bind specifically to Capan-1 cells; Supplementary Table S1. Ten highlighted lectins with specific reactivity to the pancreatic cell line 'Capan-1' as determined by high-density lectin microarray analysis; Supplementary Figure S4. Evaluation of the affinity between lectins and PDAC cell lines by flow cytometry using fluorescent labelling of the 10 lectins that were highlighted by lectin microarray; Supplementary Figure S5. Lectin histochemistry of mouse PDAC xenograft models; Supplementary Figure S6. Histochemical analysis of the top 10 highlighted lectins in a single PDAC sample; Supplementary Table S2. Summary of recently reported immunotoxins and LDC with their targets and IC50s (4-20); Supplementary Figure S7. Representative images of assays of erythrocytes from human volunteers; Supplementary Figure S8. Clinical PDAC slides stained with H&E were examined for contaminating large arterial vessels (arrows), and serial unstained slides were subjected to HRP-labelled rBC2LC-N lectin histochemistry; Supplementary Figure S9. The validation of the specificity of rBC2LC-N lectin by competition assay; Supplementary Figure S10. The rBC2LC-N lectin reactivity to human organs.
Figure S6 from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Authors: Liu Shuying , Li Shunqiang , Wang Bailiang , Liu Wenbin , Gagea Mihai , Chen Huiqin , Sohn Joohyuk , Parinyanitikul Napa , Primeau Tina , Do Kim-Anh , Vande Woude George F. , Mendelsohn John , Ueno Naoto T. , Mills Gordon B. , Tripathy Debu , Gonzalez-Angulo Ana M.
Published: April 2023

Effect of HGF on cell signaling in MET-Y1253D/PIK3CA-H1047R cells
Supplementary Figure S6 from Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model
Authors: Stallons Tania A. Rozgaja , Saidi Amal , Tworowska Izabela , Delpassand Ebrahim S. , Torgue Julien J.
Published: April 2023

There was a dose-related decrease in the mean values for WBCs (Panel A) and platelet (Panel B) numbers following each IV administration. There was partial to full recovery in mice receiving fractionated dose as compared to single dose administration.
Figure S2 from The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway
Authors: Cho Hee-Yeon , Thein Thu Zan , Wang Weijun , Swenson Stephen D. , Fayngor Rochelle A. , Ou Mengting , Marín-Ramos Nagore I. , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

Behavior study after Rolipram or NEO214 treatment.
Supplementary Figure S1 from Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model
Authors: Stallons Tania A. Rozgaja , Saidi Amal , Tworowska Izabela , Delpassand Ebrahim S. , Torgue Julien J.
Published: April 2023

A binding study of 212Pb-DOTAMTATE to AR42J, an SSTR2 expressing cell line, yielded a Kd of 12.9nM (Panel A) A dose dependent cytotoxic effect can be seen with a 50% viability observed between 12.5nCi/ml and 25nCi/ml (Panel B).
Supplemental Table 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Authors: Naik Shruthi , Galyon Gina D. , Jenks Nathan J. , Steele Michael B. , Miller Amber C. , Allstadt Sara D. , Suksanpaisan Lukkana , Peng Kah Whye , Federspiel Mark J. , Russell Stephen J. , LeBlanc Amy K.
Published: April 2023

A summary of canine patient disease types and methods to assess disease burden
Supplemental Figure 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Authors: Naik Shruthi , Galyon Gina D. , Jenks Nathan J. , Steele Michael B. , Miller Amber C. , Allstadt Sara D. , Suksanpaisan Lukkana , Peng Kah Whye , Federspiel Mark J. , Russell Stephen J. , LeBlanc Amy K.
Published: April 2023

Summary of viral shedding in a variety of biological samples
Supplemental Figure 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Authors: Naik Shruthi , Galyon Gina D. , Jenks Nathan J. , Steele Michael B. , Miller Amber C. , Allstadt Sara D. , Suksanpaisan Lukkana , Peng Kah Whye , Federspiel Mark J. , Russell Stephen J. , LeBlanc Amy K.
Published: April 2023

Representative histological sections of tumor removed from patient UTK01
Supplementary Figure S7 from Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma
Authors: Xu Kexin , Sun Geng , Li Min , Chen Hongling , Zhang Zuhao , Qian Xixi , Li Ping , Xu Lin , Huang Wenbin , Wang Xuerong
Published: April 2023

Supplementary Figure S7 shows histone acetylation was not involved in p70S6K induced downregulation of KLF4.
Supplementary Figure S3 from Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma
Authors: Xu Kexin , Sun Geng , Li Min , Chen Hongling , Zhang Zuhao , Qian Xixi , Li Ping , Xu Lin , Huang Wenbin , Wang Xuerong
Published: April 2023

Supplementary Figure S3 shows glibenclamide downregulated cyclin D1 expression and p70S6K signaling pathway in NSCLCs.
Supplementary Fig. S6 from TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Authors: Yoshimura Chihoko , Muraoka Hiromi , Ochiiwa Hiroaki , Tsuji Shingo , Hashimoto Akihiro , Kazuno Hiromi , Nakagawa Fumio , Komiya Yu , Suzuki Satoshi , Takenaka Toru , Kumazaki Masafumi , Fujita Naoya , Mizutani Takashi , Ohkubo Shuichi
Published: April 2023

Supplementary Figure S6. in vivo pharmacodynamic effects of TAS4464 in the GRANTA-519 (MCL) xenograft model (A) and SU-CCS-1 (clear cell sarcoma) xenograft model (B). Tumors were harvested at the indicated times after the administration of a single intravenous dose of TAS4464 (100 mg/kg; n = 3). 5% glucose solution was administered intravenously in the vehicle group. Pooled tumors were analyzed in (A) and individual samples were analyzed in (B). The hematoxylin-eosin staining results of SU-CCS-1 tumor sections were shown in (C), tumors were harvested on day 3 after single administration of each drugs. (D-E) Pharmacokinetic profiles of NAE inhibitors. (D) Mean pharmacokinetic profiles following intravenous administration of 50 mg/kg of TAS4464 and 60 mg/kg of MLN4924 in male Balb/c mice. (E) Plasma concentration-time profiles of TAS4464 after intravenous administration of TAS4464 to nude mice at dose of 6.3, 25.0, and 100.0 mg/kg.ã€€
Supplementary Fig. S5 from TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Authors: Yoshimura Chihoko , Muraoka Hiromi , Ochiiwa Hiroaki , Tsuji Shingo , Hashimoto Akihiro , Kazuno Hiromi , Nakagawa Fumio , Komiya Yu , Suzuki Satoshi , Takenaka Toru , Kumazaki Masafumi , Fujita Naoya , Mizutani Takashi , Ohkubo Shuichi
Published: April 2023

Supplementary Figure S5. Body weigh change during the antitumor efficacy test. (A) CCRF-CEM, low dose. (B) CCRF-CEM, high dose. (C) GRANTA-519. (D) SU-CCS-1.(E)LU5266.
Supplementary Fig. S4 from TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Authors: Yoshimura Chihoko , Muraoka Hiromi , Ochiiwa Hiroaki , Tsuji Shingo , Hashimoto Akihiro , Kazuno Hiromi , Nakagawa Fumio , Komiya Yu , Suzuki Satoshi , Takenaka Toru , Kumazaki Masafumi , Fujita Naoya , Mizutani Takashi , Ohkubo Shuichi
Published: April 2023

Supplementary Figure S4. TAS4464 gene signature. (A) Differentially expressed genes (1373 genes) between sensitive and insensitive cells (t-test, p-value<0.01). (B) Heatmap of 35 genes selected from 1373 genes based on the neddylatied protein list. (C)ã€€TAS4464 gene signature score was applied to separate predictive sensitive/insensitive cell lines. (D) Geneset of TAS4464 gene signature.
Supplementary Fig. S1 from TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Authors: Yoshimura Chihoko , Muraoka Hiromi , Ochiiwa Hiroaki , Tsuji Shingo , Hashimoto Akihiro , Kazuno Hiromi , Nakagawa Fumio , Komiya Yu , Suzuki Satoshi , Takenaka Toru , Kumazaki Masafumi , Fujita Naoya , Mizutani Takashi , Ohkubo Shuichi
Published: April 2023

Supplementary Figure S1. Synthesis procedures and characterization data for the synthesis of TAS4464.
Supplemental Figure 6 from Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Authors: Gowda Raghavendra , Kardos Gregory , Sharma Arati , Singh Sanjay , Robertson Gavin P.
Published: April 2023

Supplemental Figure 6. Tumor inhibition of Celeplum-777 compared to combined nanoliposomes containing each agent alone.
Supplementary Table S3 from Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ
Authors: Gomez-Roman Natividad , Chong Ming Y , Chahal Sandeep K. , Caragher Seamus P. , Jackson Mark R. , Stevenson Katrina H. , Dongre Sidhartha A. , Chalmers Anthony J.
Published: April 2023

Statistical analysis of MK2206 efficacy study
Supplementary Figure S4 from Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ
Authors: Gomez-Roman Natividad , Chong Ming Y , Chahal Sandeep K. , Caragher Seamus P. , Jackson Mark R. , Stevenson Katrina H. , Dongre Sidhartha A. , Chalmers Anthony J.
Published: April 2023

EGFR and VEGFR2 expression and DNA damage response in vivo. A, Representative immunohistochemistry images for pVEGFR2 of paraffin-embedded orthotopic tumours derived from intracranially injected G7 GSC (left panels) and E2 GSC (right panels), and EGFR immunohistochemistry images in G7 paraffin-embedded (PFE) orthotopic tumours as in (A). B, Following a 5 month period after intracranial injection of E2 cells, mice were treated with 10 Gy and sacrificed at different time points (0, 0.5, 2 and 24 hrs) following radiation treatment. Representative immunofluorescent images of PFE-orthotopic tumours stained for EGFR (red) and Rad51 (green) are depicted. DAPI (blue) was used for nuclear staining. C, Bioluminescence images confirming tumour engraftment CD1 nude mice injected intracranially with U87MGLuc cells on day 6. Images were acquired using a Xenogen IVIS Spectrum and Living Software.
Figure S1 from Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation
Authors: Chen Min-Bin , Liu Yuan-Yuan , Xing Zhao-Yu , Zhang Zhi-Qing , Jiang Qin , Lu Pei-Hua , Cao Cong
Published: April 2023

Figure S1. Eca-109 cells were pre-treated for 1 hour with 50 Î¼M of necrostatin-1 ("Nec-1"), or 5 Î¼M of Ferrostatin-1 ("Fer-1"), followed by itraconazole ("Itra", 3.0 Î¼g/mL) treatment for 72 hours; Cell viability (MTT assay, A) and cell death (trypan blue staining assay, B) were tested. * P < 0.05 vs. group "Ctrl".